Piper Sandler analyst Swapnil Malekar lowered the firm’s price target on Mirati Therapeutics to $68 from $87 but keeps an Overweight rating on the shares. Mirati Therapeutics priced Krazati at a slight premium vs Lumakras and justified the overage based on advantage seen in CNSmet patients and a better safety profile, but he remains cautious until this theory pans out in the real world given the brain-met language or the safety data from tablet formulation was not reflected in the label, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRTX:
- Mirati (NASDAQ:MRTX) Stock Jumps as FDA Approves Lung Cancer Drug
- Mirati Therapeutics price target raised to $87 from $84 at Piper Sandler
- Mirati Therapeutics: FDA grants accelerated approval for KRAZATI
- Stifel cuts Mirati price target to $73, says move lower ‘overdone’
- Mirati Therapeutics downgraded to Neutral from Buy at Citi (yesterday)